Although variations in the levels of sNRP1, Sema3E, and Slit2 have been proposed as a useful device to assess microcirculatory abnormalities at different stages of SSc, since all the aforementioned studies evaluated a single neurovascular guidance molecule at a time and in relatively small groups of patients, our group has performed additional research in order to simultaneously measure sNRP1, Sema3E, and Slit2 in a larger SSc cohort [117]. This evidence concerns the gene SEMA3E and systemic sclerosis.